RxDoctor Payments Data

Bharath Radhakrishna, MD

Internal Medicine · Cape Coral, FLNPI 1578550026

Payments from drug & device makers

$275in general payments, 2019–2025

Across 18 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$69
  • Merck$54
  • Novo Nordisk$34
  • Amgen$26
  • Amarin Pharma, Inc.$20
  • Boehringer Ingelheim$18
  • plus $53 from 4 others

What the payments were for

  • Food & beverage$275100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$275 in reported general payments places this provider in the 45th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$82,464
Medicare patients
246
Services billed
1,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$83,750
JardianceEmpagliflozin37$52,987
OzempicSemaglutide22$48,163
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$20,306
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$19,772
XareltoRivaroxaban13$19,610
Repatha SureclickEvolocumab16$18,859
FarxigaDapagliflozin Propanediol14$15,501
Breo ElliptaFluticasone/Vilanterol18$13,965
JanuviaSitagliptin Phosphate12$12,372
VascepaIcosapent Ethyl11$11,459
SymbicortBudesonide/Formoterol Fumarate20$6,469
BreynaBudesonide/Formoterol Fumarate16$3,818
Rosuvastatin Calcium272$3,459
Atorvastatin Calcium370$3,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$18$52,98737 claims
Novo NordiskOzempic$34$48,16322 claims
GSKTrelegy Ellipta, Breo Ellipta$11$34,27243 claims
AstraZenecaFarxiga, Symbicort$15$21,97134 claims
MerckJanuvia$54$12,37212 claims
AbbVieSynthroid$15$1,55231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Cape Coral

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →